Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2017

Year

Marianne Pavel, Simron Singh, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary, Carlo Carnaghi, Jiří Tomášek, Edward M. Wolin, Markus Raderer,

The Lancet Oncology

Gastrointestinal OncologyHealth-related QualityMedicineLung Neuroendocrine TumoursCancer ManagementEverolimus Versus PlaceboCancer TreatmentOncologyRadiation OncologyLung CancerCancer Research